Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17824312 | 0.86 | RAB9A (0.64) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL19714422 | 0.83 | MEN1 (0.52) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL19713961 | 0.83 | MEN1 (0.52) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL19713960 | 0.83 | MEN1 (0.52) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL17824318 | 0.83 | RAB9A (0.53) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL19714421 | 0.82 | DRD2 (0.63) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL17824302 | 0.82 | HTT (0.60) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL19714278 | 0.82 | ALDH1A1 (0.61) | ALDH1A1RAB9AMEN1KMT2APKM | |
| SCHEMBL17824289 | 0.81 | LMNA (0.66) | RAB9AMEN1KMT2ALMNATSHR | |
| SCHEMBL19714240 | 0.81 | RAB9A (0.59) | ALDH1A1RAB9AMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| EP-3230275-A1 | PRO-SURVIVAL COMPOUNDS | University Court of The University of Glasgow (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092327-A1 | PRO-SURVIVAL COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | MCL1, MKI67, MORF4L1 | ALDH1A1 95/4885RAB9A 2097/4885MEN1 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.